Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Novartis vows to fight U.S. price-fixing claims against Sandoz unit

Novartis said claims of price fixing against the drugmaker’s Sandoz generics unit amid a U.S. probe of 20 drugmakers are without merit, with the Swiss company vowing to fight allegations in a lawsuit.

Read More »

SK Life Science Provides Update on Recent Company Milestones and Accomplishments

SK Life Science Inc., a subsidiary of SK Biopharmaceuticals Co. Ltd., an innovative biopharmaceutical company focused on developing and bringing to market treatments for central nervous system (CNS) disorders, announced key business and scientific accomplishments from the fourth quarter of 2018 through the first quarter of 2019.

Read More »

U.S. states accuse 20 drugmakers of price fixing

U.S. states filed a lawsuit accusing Teva Pharmaceuticals USA Inc. of orchestrating a sweeping scheme with 19 other drug companies to inflate drug prices – sometimes by more than 1,000 percent – and stifle competition for generic drugs, state prosecutors said.

Read More »

Bayer to Invest $150 Million in New Cell Manufacturing Plant in Berkeley

Bayer plans to build a Cell Culture Technology Center in Berkeley, Calif., investing $150 million in the project. The center will focus on developing biologics, an area where Bayer lags behind the company’s competitors.

Read More »

Forty Seven Inc. and Acerta Enter Collaboration

Clinical-stage immuno-oncology company Forty Seven Inc. announced a collaboration with Acerta Pharma, AstraZeneca’s hematology research and development center of excellence.

Read More »

Gilead Sciences to Provide Free Truvada for PrEP to Support U.S. Initiative to End HIV Epidemic

Gilead Sciences Inc. announced that the company will donate Truvada for PrEP (emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg tablets) to the U.S. CDC.

Read More »

Four Biotech Companies List on the Nasdaq Today

Four biotech companies began trading on the Nasdaq this morning.

Read More »

Novartis buys dry-eye drug from Takeda for up to $5.3 billion

Novartis is buying the projected blockbuster dry-eye drug Xiidra from Takeda Pharmaceutical for up to $5.3 billion.

Read More »

GSK-Pfizer deal gets approval from Australia’s anti-trust watchdog

GlaxoSmithKline’s deal to buy Pfizer’s consumer healthcare business will not lesson competition in Australia, the country’s anti-trust regulator said.

Read More »

Sarepta Adds Sixth LGMD Gene Therapy Candidate to Company’s Arsenal

Cambridge, Mass.-based Sarepta Therapeutics snagged an exclusive option for a gene therapy candidate to treat Limb-girdle muscular dystrophy type 2A (LGMD2A).

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

April 2019 Focus: Healthcare agency & network profiles, industry overview & awards, and more!


Ad Right Bottom